Abstract
PURPOSE: Inappropriate empiric treatment of ventilator-associated pneumonia (VAP) increases mortality. Pseudomonas aeruginosa (PA), the cause of ¼ of all VAP, is increasingly resistant to conventional antibiotics. The rates of PA-VAP susceptibility to doripenem (DOR) (81.5%) are higher than to imipenem (IMI) (74.1%)[1]. While 7.8% of isolates resistant to IMI are sensitive to DOR (DOR-S), only 0.4% of DOR-resistant PA is sensitive to IMI (IMI-S)[1]. We developed a model to quantify outcome differences between strategies of empiric treatment of VAP with DOR vs. IMI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
